Medication Monitor



SORT BY:      Most Recent      Most Viewed     
List-View      Table-View
Generic Name (Trade Name—Company)
Notes
  • June 22, 2011

    Uses:

    Treatment of moderate to severe pain associated with chronic anal fissures 

    Rectiv is the only FDA-approved prescription product for patients with this condition. Accoding to a company press release, the ointment will be available in a 0.4% strength in the first quarter of 2012.

     

  • June 22, 2011

    Nature Relief has initiated a voluntary recall of this wart and mole remover kit because use may result in harmful burns to the skin. The active ingredient, calcium oxide, can cause burns to the skin, and FDA has received a report of burns to the skin after use of the product that required medical attention. Only a small quantity of this product was sold via direct to consumer Internet marketing; patients inquiring about this product should be informed of the recall and told to place any unused product in a plastic bag for safe disposal.   

  • June 20, 2011

    Uses:

    Management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate     

    Pfizer and Acura announced the approval of Oxecta, an immediate-release formulation of oxycodone tablets with specialized technology to decrease tampering associated with opioid abuse and misuse. The AVERSION technology comprises a unique composition of commonly used pharmaceutical ingredients.  

     

  • June 20, 2011

    Uses:

    Treatment of susceptible bacterial infections

    FDA announced that the first generic versions of levofloxacin tablets, oral solution, and injectable solution have been approved. Twelve manufacturers have approved applications for levofloxacin: Akorn, Aurobindo Pharma, Dr. Reddy’s Laboratories, Glenmark Generics, Hi-Tech Pharmacal, Lupin, Mylan, Sagent Strides, Sandoz, Teva, Torrent, and Wockhardt. The drug is indicated for the treatment of susceptible bacterial infections including acute sinusitis, acute exacerbations of chronic bronchitis, nosocomial or community-acquired pneumonia, urinary tract infections, acute pyelonephritis, chronic bacterial prostatitis, and skin and skin structure infections. Levofloxacin is also indicated to reduce incidence or progression of disease following exposure to inhalational anthrax. 

  • June 17, 2011

    Ortho-McNeil-Janssen is initiating a voluntary recall of one lot of Risperdal (risperidone) 3 mg tablets (Lot #0GG904, Expiration Date May 2012, NDC #50458-330-06) and one lot of risperidone 2 mg tablets (Lot #0LG175, Expiration Date Aug 2012, NDC #50458-593-60 ), marketed by Patriot Pharmaceuticals. Both are packaged in bottles containing 60 tablets. The recalls stem from two consumer reports of an uncharacteristic odor thought to be caused by trace amounts of 2,4,6 tribromoanisole (TBA). Although not considered to be toxic, TBA can generate an offensive odor and a very small number of patients have reported temporary gastrointestinal symptoms when taking other products with this odor.

     

     

     

Pages